Sadra Medical Journal

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

Peer Review Process

The Effect of Psychiatric Drugs on Blood Glucose and Lipid in Patients

Document Type : Review Article

Authors

1 Ph.D. in nursing education, assistant professor and faculty member of Qazvin University of Medical Sciences, Qazvin, Iran

2 MSc Student of Psychiatric Nursing, Qazvin University of Medical Sciences, Qazvin, Iran

Abstract

Psychiatric disorders are highly prevalent among clients referred to primary care and general practitioners. Given that the main core of treatment in these patients is medication, these psychiatric drugs can cause long-term complications such as a decrease or increase in blood glucose and lipid. In this review study, the effects of these drugs on blood glucose and lipid in Iran have been addressed. It should be noted that blood glucose and lipid levels can be affected by several factors including environmental factors, geography, race, ethnicity, and even skin color. Moreover, many relevant studies approved the relationships among these variables repeatedly. In this review study, international databases of Web of Knowledge, ISI, PubMed, Google Scholar, SID, and Noormags databases (as national ones) were searched up to the end of 2019. Finally, eight studies out of 30 were investigated. The Total number of subjects studied in this study was 824 in 8 articles, which included six clinical trials, one descriptive study, and one case-control study. In general, in the present review study, most studies indicate the increasing effect of serotonin-dopamine antagonist antipsychotics on blood glucose (so clozapine and then risperidone, from this drug class, have a greater effect on the development of this complication), as well as the effects of dopamine antagonist antipsychotics on lipid profile in patients. Comparing clomipramine and fluoxetine, clomipramine increased blood glucose and lipids, but fluoxetine did not have these complications.

Keywords

References
  1. Serrano- blanco A, Palao DJ, Luciano JV, PintoMeza A, Lujan L, Fernandez A. Prevalence of mental disorders in primary care: Results from the diagnosis and treatment of mental disorders in primary care study (DASMAP). Soc Psychiatry Psychiatr Epidemiol 2009; 45: 201-10.
  2. Sharifi V, Daliri S, Amini H, Mohammadi M. Psychiatric Problems in General Outpatient Clinics: Prevalence and Reasons for Help Seeking. IJPCP 2011;16(4):484-9. (In Persian)
  3. Sadock VA, Sadock BJ. Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia: Lippincott, Williams & Wilkins; 2007.
  4. Fadai F. The important role of mental disorder in social problems. J Rehabil 2007; 29: 6-7. (in Persian)
  5. Preskorn SH. Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA. 1997; 277: 682.
  6. Ferslew KE, Hagardorn AN, HarlanGC, McCormick WE. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci. 1998; 43: 1082-1085.
  7. Preskorn SH. Fatal drug interactions as a differential consideration in apparent suicides. J Psych Prac 2002; 8: 233_238.
  8. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C, Parkinson Study Group. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997;48(4):1070-6.
  9. Roughead E, Mc dermott B, Gilbert A. Antideppressants: prevalence of duplicate therapy and avoidable drug interactions in Australian veterans. Australian and New Zeland Journal of Psychiatry 2007; 41:366-370.
  10. Robinson RF, Nahata MC, Olshefski RS. Syncope associated with concurrent amitriptyline and fluconazole therapy. Ann Pharmacother. 2000; 34: 1406-1409.
  11. Spigset O, Hedenmalm K, Dahl ML, Wiholm BE, Dahlqvist R. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiater Scand 1997; 96: 379_384.
  12. Preskorn SH. I don't see'em. J Pract Psychiatry Behav Health. 1997; 3: 302-307.
  13. Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving tge selective serotonin reuptake inhibitor, paroxetine J Psychofarmacol. 1999; 13:313-317.
  14. Noorbala A, Damari B, Riyazi Esfehani S. Evaluation of mental disorders incidence trend in Iran. Daneshvar (Medicine) Shahed University 2014; 21:112. (In Persian)
  15. Mahmood-Abadi HZ, Kayhani M, Rabi M, Mohammadi MR. A survey of knowledge and attitude of nonpsychiatrists (medical specialists) treating major depression. Thrita 2012; 1:30-3.
  16. Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Preference and Adherence 2017; 11:449.
  17. Gharakhani M, Razeghi Jahromi S, Sadeghian H, Faghihzadeh S, Kazemi H, Arabkheradmand J. Potential drug interactions in war-injured veterans. Iranian J of War and public Health. 2010; 8: 23-28.
  18. Coelho PVV, Brum CA. Interactions between antidepressant and antihypertensive and glucose lowering drugs lowering drugs among patients in the HIPERDIA program, coronel Fabriciano, Minas Gerais State, Brazil. 2009; 25:2229-2236.
  19. Fakhary Ali. Comparison of the effect of olanzapine and haloperidol on blood glucose in schizophrenic and schizoaffective patients. Tabriz University of Medical Science [Dissertation]; 2009.
  20. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L. Usefulness of fluoxetine in obese non‐insulin‐dependent diabetics: A multicenter study. Obesity research. 1996;4(4):391-6.
  21. Jiwa M, Gudes O, Varhol R, Mullan N. Impact of geography on the control of type 2 diabetes mellitus: a review of geocoded clinical data from general practice. BMJ open. 2015; 5(12): 9504.
  22. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, De Gregorio M, Ravussin E, Knowler WC, Bennett PH, Howard BV, Bogardus C. Racial differences in the relation between blood pressure and insulin resistance. New England Journal of Medicine. 1991 Mar 14; 324(11):733-9.
  23. Kanaley JA, Giannopoulou I, Tillapaugh-Fay G, Nappi JS, Ploutz-Snyder LL. Racial differences in subcutaneous and visceral fat distribution in postmenopausal black and white women. Metabolism-Clinical and Experimental. 2003; 52(2):186-91.
  24. Residori L, García-Lorda P, Flancbaum L, Pi-Sunyer FX, Laferrère B. Prevalence of co-morbidities in obese patients before bariatric surgery: effect of race. Obesity surgery. 2003; 13(3):333-40.
  25. Voeks JH, McClure LA, Go RC, Prineas RJ, Cushman M, Kissela BM, Roseman JM. Regional differences in diabetes as a possible contributor to the geographic disparity in stroke mortality: the REasons for Geographic and Racial Differences in Stroke Study. Stroke. 2008; 39(6):1675-80.
  26. Campbell JA, Walker RJ, Smalls BL, Egede LE. Glucose control in diabetes: the impact of racial differences on monitoring and outcomes. Endocrine. 2012; 42(3):471-82.
  27. Mohammadi MR, Momeni F, Torkzaban R, Ghaely P. The Effects of Fluoxetine and Clomipramine on Blood Sugar, Cholesterol, and Weight of Obsessive-Compulsive Children and Adolescents. Iranian Journal of Psychiatry and Clinical Psychology. 2003;8(3):12-9.
  28. Roohafza H, Khani A, Afshar H, Yazdekhasti S, GOLSHAHI J. Comparing the effect of atypical and conventional antipsychotics on lipid profile. Journal of Isfahan Medical School. 2015; 32 (319): 2394-2400.
  29. Mousavi Z, Abdollahian E, Karimian S, Rokni H. Typic and Atypic Antipsychotic Drugs: Comparison of Their Effects on Blood Sugar in Schizophrenic Patients. Medical Journal of Mashhad University of Medical Sciences 2012; 55(3): 139-143.
  30. Safa M, Saki M, Mohammadi M R, Delfan B, Tarrahi M J, Rouhandeh M. Comparative study of adverse effects of Olanzapine and Risperidone on blood sugar, lipid and other side effects in psychotic disorders. Yafte 2008; 10 (3):3-11. (In Persian)
  31. Masoudzadeh A, Mahmoodi M, Torabizadeh J, Onagh M. Comparison of the Effects of Clozapine, Olanzapine and Risperidone with Haloperidol on Fasting Blood Level of Glucose, Cholesterol and Triglyceride in Patients with Psychotic Disorders. JBUMS 2009; 11 (2):25-30.
  32. Omranifard V، Pirzade A. Comparison of the Effects of Drugs of Tipic Anti psychiatric and olanzapine on Fasting Blood Level of Glucose, in psychotic disorders 2006;15(53):25-31.
  33. Modabernia M, Shojaee Tehrani H, Jalaly H. The Study of Mean Changes in Fasting Glucose Level and BMI in Psychotic Patients Treated with Olanzapine in Shafa Hospital and Private Clinics of Rasht in 2005-2006. Jour Guilan Uni Med Sci. 2007; 15 (60) :17-25. (In Persian)
  34. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70(1): 1-17.
  35. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157(6): 975-81.
  36. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59(11): 1021-6.

Sadra Medical Journal
Volume 8, Issue 2
April 2020
Pages 193-202
Files
Share
How to cite
Statistics